Tonghua Dongbao Pharmaceutical Co., Ltd.

XSSC:600867 Stock Report

Market Cap: CN¥16.5b

Tonghua Dongbao Pharmaceutical Valuation

Is 600867 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600867 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600867 (CN¥8.49) is trading above our estimate of fair value (CN¥0.16)

Significantly Below Fair Value: 600867 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600867?

Key metric: As 600867 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600867. This is calculated by dividing 600867's market cap by their current earnings.
What is 600867's PE Ratio?
PE Ratio48.5x
EarningsCN¥341.31m
Market CapCN¥16.55b

Price to Earnings Ratio vs Peers

How does 600867's PE Ratio compare to its peers?

The above table shows the PE ratio for 600867 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.9x
600420 Shanghai Shyndec Pharmaceutical
15.2x16.0%CN¥16.4b
600216 Zhejiang Medicine
15.6x15.2%CN¥15.3b
300026 Tianjin Chase Sun PharmaceuticalLtd
73.2x34.4%CN¥12.1b
002773 Chengdu Kanghong Pharmaceutical Group
15.6x13.4%CN¥18.6b
600867 Tonghua Dongbao Pharmaceutical
48.5x69.7%CN¥16.5b

Price-To-Earnings vs Peers: 600867 is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the peer average (29.9x).

Price to Earnings Ratio vs Industry

How does 600867's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600867 48.5xIndustry Avg. 31.5xNo. of Companies32PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600867 is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the CN Pharmaceuticals industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 600867's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600867 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.5x
Fair PE Ratio60.5x

Price-To-Earnings vs Fair Ratio: 600867 is good value based on its Price-To-Earnings Ratio (48.5x) compared to the estimated Fair Price-To-Earnings Ratio (60.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600867 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥8.49
CN¥10.45
+23.1%
14.6%CN¥12.00CN¥8.00n/a4
Nov ’25CN¥8.47
CN¥10.45
+23.4%
14.6%CN¥12.00CN¥8.00n/a4
Oct ’25CN¥8.77
CN¥11.37
+29.6%
16.6%CN¥14.08CN¥9.00n/a4
Sep ’25CN¥7.95
CN¥12.61
+58.6%
14.0%CN¥14.36CN¥10.00n/a4
Aug ’25CN¥8.07
CN¥12.61
+56.3%
14.0%CN¥14.36CN¥10.00n/a4
Jul ’25CN¥8.48
CN¥12.86
+51.7%
11.0%CN¥14.36CN¥11.00n/a4
Jun ’25CN¥9.18
CN¥13.36
+45.5%
10.2%CN¥14.36CN¥11.00n/a4
May ’25CN¥10.09
CN¥14.77
+46.4%
4.5%CN¥15.73CN¥14.00n/a4
Apr ’25CN¥10.92
CN¥15.27
+39.9%
7.8%CN¥17.00CN¥14.00n/a4
Mar ’25CN¥10.32
CN¥15.24
+47.7%
7.7%CN¥17.00CN¥14.00n/a4
Feb ’25CN¥9.32
CN¥15.24
+63.5%
7.7%CN¥17.00CN¥14.00n/a4
Jan ’25CN¥10.83
CN¥14.53
+34.2%
6.0%CN¥16.00CN¥13.76n/a4
Dec ’24CN¥11.91
CN¥14.53
+22.0%
6.0%CN¥16.00CN¥13.76n/a4
Nov ’24CN¥11.29
CN¥13.75
+21.8%
10.5%CN¥16.00CN¥12.00CN¥8.474
Oct ’24CN¥10.73
CN¥13.27
+23.6%
8.3%CN¥15.00CN¥12.00CN¥8.774
Sep ’24CN¥9.72
CN¥12.71
+30.8%
7.0%CN¥14.00CN¥11.50CN¥7.955
Aug ’24CN¥10.20
CN¥13.67
+34.0%
8.6%CN¥15.00CN¥11.50CN¥8.075
Jul ’24CN¥10.44
CN¥13.67
+30.9%
8.6%CN¥15.00CN¥11.50CN¥8.485
Jun ’24CN¥11.36
CN¥13.67
+20.3%
8.6%CN¥15.00CN¥11.50CN¥9.185
May ’24CN¥11.90
CN¥13.07
+9.8%
13.7%CN¥14.24CN¥9.50CN¥10.095
Apr ’24CN¥11.84
CN¥11.30
-4.6%
14.7%CN¥14.00CN¥9.50CN¥10.924
Mar ’24CN¥11.36
CN¥11.05
-2.8%
11.5%CN¥13.00CN¥9.50CN¥10.324
Feb ’24CN¥9.86
CN¥10.80
+9.5%
8.4%CN¥12.00CN¥9.50CN¥9.324
Jan ’24CN¥9.18
CN¥10.80
+17.6%
8.4%CN¥12.00CN¥9.50CN¥10.834
Dec ’23CN¥9.28
CN¥10.80
+16.4%
8.4%CN¥12.00CN¥9.50CN¥11.914
Nov ’23CN¥8.92
CN¥10.47
+17.4%
13.4%CN¥12.00CN¥8.20CN¥11.294

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.2b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.36

7D

-4.1%

1Y

-21.9%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.11

7D

-5.1%

1Y

14.5%

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.75

7D

-0.1%

1Y

16.1%